Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.910 +0.680 (+21.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 ... 17 18 19 20 21 22 23 24 Next > CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology February 18, 2022 Via Investor Brand Network Following Sildenafil Study, Lexaria (NASDAQ: LEXX) Announces Plans for More Studies in 2022 February 17, 2022 Via Investor Brand Network Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022 February 16, 2022 Via Investor Brand Network Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated as Treatment for Multiple Conditions February 14, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions February 11, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions February 11, 2022 Via CannabisNewsWire Lexaria (NASDAQ: LEXX) Technology Shows Promise in Improving Performance of ED Drugs February 11, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs February 11, 2022 Via Investor Brand Network Lexaria (NASDAQ: LEXX) CEO Summarizes 2021 Milestones in Letter to Shareholders February 09, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders February 08, 2022 Via Investor Brand Network Lexaria Bioscience (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study February 03, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study February 02, 2022 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study February 02, 2022 Via Investor Brand Network Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study February 02, 2022 DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... From Lexaria Bioscience Corp. Via AccessWire Lexaria (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Tech on EDGE Podcast February 01, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast January 31, 2022 Via Investor Brand Network Lexaria (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study January 28, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study January 27, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update January 27, 2022 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update January 27, 2022 Via Investor Brand Network Lexaria Provides Annual Letter From the CEO January 27, 2022 KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an... From Lexaria Bioscience Corp. Via AccessWire Lexaria Bioscience (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs January 21, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval January 20, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview January 20, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview January 20, 2022 Via CannabisNewsWire Lexaria Bioscience (NASDAQ: LEXX) Comments on Study Examining Cannabinoids and SARS-CoV-2 January 19, 2022 Via Investor Brand Network Topics Cannabis Exposures Cannabis CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2 January 18, 2022 Via Investor Brand Network Topics Cannabis Exposures Cannabis CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2 January 18, 2022 Via CannabisNewsWire Topics Cannabis Exposures Cannabis Lexaria Bioscience (NASDAQ: LEXX) Leveraging DehydraTECH(TM) for More Effective Oral Medicine January 18, 2022 Via Investor Brand Network Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2 January 18, 2022 "Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"... From Lexaria Bioscience Corp. Via AccessWire < Previous 1 2 ... 17 18 19 20 21 22 23 24 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.